Nurix Therapeutics (NRIX) Short-term Investments (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Short-term Investments data on file, last reported at $469.5 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $469.5 million, down 0.89% year-over-year; the trailing twelve-month figure through Feb 2026 was $469.5 million (down 0.89% YoY), and the FY2025 annual result was $346.0 million, down 30.75% from the prior year.
• Short-term Investments rose to $469.5 million in Q1 2026 per NRIX's latest filing, from $346.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $499.6 million in Q4 2024 and troughed at $183.2 million in Q1 2022.
• A 5-year average of $312.1 million and a median of $296.9 million in 2022 frame the typical range for Short-term Investments.
• On a YoY basis, Short-term Investments climbed as much as 143.98% in 2025 and fell as far as 30.75% in 2025.
• A 5-year view of Short-term Investments shows it stood at $244.7 million in 2022, then decreased by 4.65% to $233.3 million in 2023, then soared by 114.16% to $499.6 million in 2024, then plunged by 30.75% to $346.0 million in 2025, then soared by 35.71% to $469.5 million in 2026.
• Business Quant data shows NRIX's Short-term Investments at $469.5 million in Q1 2026, $346.0 million in Q4 2025, and $350.4 million in Q3 2025.